Glycine

Glycine

SCHEMBL583138

NCC(=O)O.O=C([O-])O.[K+]

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OR51E2 Q9H255 2/20 0.71
GLRA1 P23415 1/20 0.71
SLC6A9 P48067 1/20 0.71
GABRR1 P24046 4/20 0.43
BLM P54132 3/20 0.39
KMT2A Q03164 3/20 0.39
LDHA P00338 2/20 0.39
MEN1 O00255 2/20 0.39
LMNA P02545 4/20 0.38
TSHR P16473 4/20 0.38
THRB P10828 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
GABRR3 A8MPY1 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
HDAC3 O15379 1/20 0.38
GABBR2 O75899 1/20 0.38
CYP1A2 P05177 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL16600 0.93 GLRA1 (0.71) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL2586653 0.93 OR51E2 (0.71) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL27455875 0.93 OR51E2 (0.71) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL25362123 0.90 OR51E2 (0.67) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL25333179 0.90 OR51E2 (0.67) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL25331377 0.90 GLRA1 (0.67) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL6237269 0.86 OR51E2 (0.71) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL978831 0.86 GLRA1 (0.71) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL7078758 0.86 OR51E2 (0.71) OR51E2GLRA1SLC6A9GABRR1BLM
Glycine SCHEMBL6237177 0.86 OR51E2 (0.71) OR51E2GLRA1SLC6A9GABRR1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4496874-A1 A SOLID HARD SURFACE CLEANING COMPOSITION Unilever IP Holdings B.V. (NL) 2025-01-29 EP claimed
CN-118974224-A Solid hard surface cleaning compositions 联合利华知识产权控股有限公司 2024-11-15 CN claimed
WO-2023180053-A1 A SOLID HARD SURFACE CLEANING COMPOSITION UNILEVER IP HOLDINGS B.V. (NL) 2023-09-28 WO claimed
CN-111803442-B Stabilizer for improving bioavailability of ammonium glycyrrhetate S liquid dosage form and application thereof 广州一品红制药有限公司 2022-06-14 CN claimed
CN-111803442-A Stabilizer for improving bioavailability of ammonium glycyrrhetate S liquid dosage form and application thereof 广州一品红制药有限公司 2020-10-23 CN claimed
US-6077536-A AMOXYCILLIN HYDRATE AND EFFERVESCENT ACID AND BASE COUPLE BEECHAM GROUP PLC (GB) 2000-06-20 US claimed
US-6051254-A AMOXYCILLIN HYDRATE, AN EFFERVESCENT COUPLE, BETA.-LACTAMASE INHIBITOR; THE EFFERVESCENT COUPLE COMPRISES AN ACID COMPONENT AND AN ALKALINE COMPONENT SMITHKLINE BEECHAM PLC (GB) 2000-04-18 US claimed
US-20260085255-A1 LAUNDRY COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2026-03-26 US disclosed
US-20260085254-A1 LAUNDRY COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2026-03-26 US disclosed
EP-4663737-A1 LAUNDRY UNIT DOSE PRODUCT Unilever IP Holdings B.V. (NL) 2025-12-17 EP disclosed
EP-4663738-A1 LAUNDRY UNIT DOSE PRODUCT Unilever IP Holdings B.V. (NL) 2025-12-17 EP disclosed
EP-4658745-A1 LAUNDRY COMPOSITION Unilever IP Holdings B.V. (NL) 2025-12-10 EP disclosed
EP-4584357-A1 LAUNDRY COMPOSITION Unilever IP Holdings B.V. (NL) 2025-07-16 EP disclosed
US-20160220481-A1 Low-Sodium Effervescent Pharmaceutical Formulations EFFRX PHARMACEUTICALS SA (CH) 2016-08-04 US disclosed
EP-3046549-A1 LOW-SODIUM EFFERVESCENT PHARMACEUTICAL FORMULATIONS Effrx Pharmaceuticals SA (CH) 2016-07-27 EP disclosed
WO-2015040460-A1 LOW-SODIUM EFFERVESCENT PHARMACEUTICAL FORMULATIONS EFFRX PHARMACEUTICALS SA (CH) 2015-03-26 WO disclosed
EP-1931222-B1 GELLING COMPOSITIONS AND METHODS FMC BIOPOLYMER AS (NO) 2012-02-15 EP disclosed
EP-1931222-A2 GELLING COMPOSITIONS AND METHODS FMC Biopolymer AS (NO) 2008-06-18 EP disclosed
US-20070087038-A1 GELLING COMPOSITIONS AND METHODS FMC BIOPOLYMER AS (NO) 2007-04-19 US disclosed
WO-2007039294-A2 GELLING COMPOSITIONS AND METHODS FMC BIOPOLYMER AS (NO) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085255-A1 LAUNDRY COMPOSITION MGAM, GYS2, GALK1 OR51E2 4699/4885GLRA1 3842/4885SLC6A9 807/4885
US-20260085254-A1 LAUNDRY COMPOSITION MGAM, TREH, GALK1 OR51E2 4607/4885GLRA1 3148/4885SLC6A9 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.